Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial

BACKGROUND: Acyclovir (ACV) given to HSV-2 positive women after 36 weeks reduces adverse outcomes but its benefit at lower gestation was undocumented. We determined the effect of oral acyclovir administered from 28 to 36 weeks on premature rupture of membranes (PROM) primarily and preterm delivery r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakubulwa, Sarah, Kaye, Dan K., Bwanga, Freddie, Tumwesigye, Nazarius Mbona, Nakku-Joloba, Edith, Mirembe, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335854/
https://www.ncbi.nlm.nih.gov/pubmed/28253893
http://dx.doi.org/10.1186/s12978-017-0292-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335854/
https://www.ncbi.nlm.nih.gov/pubmed/28253893
http://dx.doi.org/10.1186/s12978-017-0292-7

Ejemplares similares